Alternatives to conventional hormone replacement therapy

Comprehensive Therapy

Volumn 23, Issue 8, 1997, Pages 514-532

  Taylor, Maida ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORON; CALCIUM; CHROMIUM; CLIMARAL; CONJUGATED ESTROGEN; DIETHYLSTILBESTROL; ESTRADIOL; ESTROGEN; ESTRONE; ETHINYLESTRADIOL; MAGNESIUM; PHYTOESTROGEN; PLANT EXTRACT; PRASTERONE; PROGESTERONE; UNCLASSIFIED DRUG; VITAMIN D;

ALTERNATIVE MEDICINE; ANTICOAGULATION; ARTICLE; BLEEDING; CANCER RISK; DIET SUPPLEMENTATION; FEMALE; HERBAL MEDICINE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; MENOPAUSE; PATIENT ATTITUDE; PHOTOSENSITIVITY DISORDER; POSTMENOPAUSE OSTEOPOROSIS;

ADULT; ATTITUDE TO HEALTH; COMPLEMENTARY THERAPIES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, NON-STEROIDAL; FEMALE; HUMANS; ISOFLAVONES; MENOPAUSE; MIDDLE AGED; MINERALS; PHYTOESTROGENS; PLANT PREPARATIONS; PLANTS, MEDICINAL; TREATMENT REFUSAL; VITAMINS;

EID: 0030752117     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (88)

1. Marwick C. Growing use of medicinal botanicals forces assessment by drug regulators. JAMA. 1995;273:607-609.
2. Marwick C. Learning how phytochemicals help fight disease. JAMA. 1995;274:1328-1330.
3. Lipp FJ. The efficacy, history, and politics of medicinal plants. Alternative Therapies in Health and Med. 1996;2:36-41.
4. Koff RS. Herbal hepatotoxicity: revisiting a dangerous alternative. JAMA. 1995;273:502.
5. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
6. Sullivan JM, Vander Zwaag R, Hughes JP, et al. Estrogen replacement and coronary artery disease: effect on survival in post menopausal women. Arch Int Med. 1990;150:2557-2562.
7. Sullivan JM, El-Zeky F, Vander Zwaag R, Ramanathan KB. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am J Cardiol 1997;79:847-850.
8. O'Brien JE, Peterson ED, Keeler GP, et al. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. J Am Coll Cardiol. 1996;28: 1111-1118.
9. O'Keefe JH Jr, Kim SC, Hall RR, Cochran VC, Lawhorn SL, McCallister BD. Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol. 1997;29:1-5.
10. Vandenbroucke JP. How much of the cardioprotective effect of postemenopausal estrogens is real? Epidemiology. 1995;6:207-208.
11. Hemminki E. A review of postmenopausal hormone therapy recommendations: potential for selection bias. Obstet Gynecol. 1993;82:1021-1028.
12. Matthews KA, Kuller LH, Wing RR, Meilahn EN, Pantinga P. Prior to use of estrogen replacement therapy: are users healthier than nonusers? Am J Epidemiol. 1996;15:971-978.
13. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85:304-313.
14. Col NF, Eckman MH, Karas RH, et al. Patient specific decisions about hormone replacement therapy in postmenopausal women. JAMA. 1997;277:1140-1147.
15. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women: Study of Osteoporotic, Fractures Research Group. Ann Intern Med. 1995;122:9-16.
16. Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density: the Rancho Bernardo Study. JAMA. 1997;277:543-547.
17. Seaman B. The Doctors' Case Against the Pill. New York, NY: P.H. Wyden; 1969.
18. Seaman B, Seeman G. Women and the Crisis in Sex Hormones. New York, NY: Rawson Associates; 1977.
19. Love S, Lindsey K. Dr. Susan Love's Hormone Book: Making Informed Choices About Menopause. New York, NY: Random House; 1997.
20. Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial Writing Group. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 1995;273:199-208.
21. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453-461.
22. Reubinoff BE, Wurtman J, Rojansky N, et al. Effects of hormone replacement therapy on weight, body composition, fat distribution, and food intake in early postmenopausal women: a prospective study. Fertil Steril. 1995;64:963-968.
23. O'Sullivan AJ, Hoffman DM, Ho KKY. Estrogen, lipid oxidation and body fat. N Engl J Med. 1995;333:669-670.
24. Haarbo J, Marslew U, Gotfredsen A, Christiansen C. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism. 1991; 40:1323-1326.
25. Prior JC. No adverse effects of medroxyprogesterone treatment without estrogen in postmenopausal women: double blind, placebo controlled crossover trial. Obstet Gynecol. 1994;83:24-28.
26. Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ. Effect of calcium supplementation on bone loss in postmenopausal women. N Engl J Med. 1993;18;328. Published erratum appears in N Engl J Med. 1993;329:1281.
27. Recker RR, Davies KM, Hinders SM, Heaney RP, Stegman MR, Kimmel DB. Bonegain in young adult women. JAMA. 1992;268:2403-2408.
28. Ettinger B, Genant HK, Cann CE. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Intern Med. 1987;106:40-45.
29. Johnston CC Jr, Miller JZ, Slemenda CW, et al. Calcium supplementation and increases in bone mineral density in children. N Engl J Med. 1992;327:82-87.
30. Hansen C, Werner E, Erbes HJ, Larrat V, Kaltwasser JP. Intestinal calcium absorption from different calcium preparations: influence of anion and solubility. Osteoporos Int. 1996;6:386-393.
31. Special Report. Yes, but which calcium supplement? Tufts Univ Health and Nutrit Letter. 1997;14:4-5.
32. Nielsen FH. Studies on the relationship between boron and magnesium which possibly affects the formation and maintenance of bones. Magnesium and Trace Elements. 1990;9:61-69.
33. Volpe SJ, Taper LJ, Meacham S. The relationship between boron and magnesium status and bone mineral density in the human: a review. Magnesium Research. 1993;6:291-296.
34. McCarty MF. Homologous physiological effects of phenformin and chromium picolinate. Med Hypotheses. 1993;41: 316-324.
35. Lukaski HC, Bolonchuk WW, Siders WA, Milne DB. Chromium supplementation and resistance training: effects on body composition, strength, and trace element status of men. Am J Clin Nutr. 1996;63:954-965.
36. Stearns DM, Wise JP Sr, Patierno SR, Wetterhahn KE. Chromium (III) picolinate produces chromosome damage in Chinese hamster ovary cells. FASEB J. 1995;9:1643-1648.
37. Gloth FM III, Gundberg CM, Hollis BW, Haddad JG Jr, Tobin JD. Vitamin D deficiency in homebound elderly persons. JAMA. 1995;274:1683-1686.
38. Valente M, Bufalino L, Castiglione GN, et al. Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass. Calcif Tissue Int. 1994;54:377-380.
39. Knekt P, Jarvinen R, Reunanen A, Maatela J. Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ. 1996;312:478-481.
40. Rimm EB, Katan MB, Ascherio A, Stampfer MJ, Willett WC. Relation between intake of flavonoids and risk for coronary heart disease in male health professionals. Ann Intern Med. 1996;125:384-389.
41. Anderson JW, Johnstone BM, Cook-Newell ME. Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med. 1995;333:276-282.
42. Persky V, Van Horn L. Epidemiology of soy and cancer: perspectives and directions. J Nutr. 1995;125(suppl 3):709S-712S.
43. Knight DC, Eden JA. A review of the clinical effects of phytoestrogens. Obstet Gynecol 1996;87:897-904.
44. Mirkin G. Estrogen in Yams. JAMA. 1991;265:912.
45. Lee JR. Natural Progesterone: The Multiple Roles of a Remarkable Hormone. Sebastopol, CA: BLL Publishing; 1993.
46. Lee JR. Osteoporosis reversal: the role of progesterone. Int Clin Nutr Rev. 1990;10:384-391.
47. Abdalla HI, Hart DM, Lindsay R, Leggate I, Hooke A. Prevention of bone mineral loss in postmenopausal women by norethisterone. Obstet Gynecol. 1985;66:789-792.
48. Gallagher JC, Kable WT, Goldgar D. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med. 1991;90:171-178.
49. Ross AH, Boyd ME, Colgan TJ, Ferenczy A, Fugere P, Lorrain J. Comparison of transdermal and oral sequential gestagen in combination with transdermal estradiol: effects on bleeding patterns and endometrial histology. Obstet Gynecol. 1993;82:773-779.
50. ACOG Technical Bulletin #166 Hormone Replacement Therapy. Washington, DC: American College of Obstetricians and Gynecologists. 1992
51. Kim S, Korhonen M , Wilborn W, et al. Antiproliferative effects of low-dose micronized progesterone. Fertil Steril. 1996;65:323-331.
52. Gillet JY, Andre G, Faguer B. Induction of amenorrhea during hormone replacement therapy: optimal micronized progesterone dose: a multicenter study. Maturitas. 1994;19:103-115.
53. Hargrove JT, Maxson WS, Wentz AC, Burnett LS. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol. 1989;73:606-612.
54. Speroff L, Rowan J, Symons J, Genant H, Wilborn W (the CHART Study Group). The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study): a randomized controlled trial. JAMA. 1996:276:1397-1403.
55. Lemon HM. Estriol prevention of mammary carcinoma induced by 7,12-dimethylbenzanthracene and procarbazine. Cancer Res. 1975;35:1341-1353.
56. Lemon HM. Pathophysiologic considerations in the treatment of menopausal patients with oestrogens: the role of oestriol in the prevention of mammary carcinoma. Acta Endocrinol (Copenh). 1980;233(suppl):17-27.
57. Dickinson LE, MacMahon B, Cole P. Brown JB. Estrogen profiles of Oriental and Caucasian women in Hawaii. N Engl J Med. 1974;291:1211.
58. Follingstad AH. Estriol: the forgotten estrogen? JAMA. 1978; 239:29-30.
59. Sedransk N, Kelley RM, Ansfield FJ, Ravdin RG, Talley RW, Potter NR. Diethylstilbestrol: recommended dosages for different categories of breast cancer patients: report of the Cooperative Breast Cancer Group. JAMA. 1977;237(19): 2079R-2088R.
60. Holzer D, Harvey HA, Lipton A. Comparison of DES vs DES + chlorambucil in women with first recurrence of breast cancer. J Surg Oncol. 1979;12:1-9.
61. Whitehead MI. Prevention of endometrial abnormalities. Acta Obstet Gynecol Scand. 1986;134(suppl):81-91.
62. Padwick ML, Siddle NC, Lane G, et al. Oestriol with oestradiol vesus oestradiol alone: a comparison of endometrial, symptomatic, and psychological effects. Br J Obstet Gynecol. 1986;93:606.
63. Jones KP. Estrogens and progestins: what to use and how to use it. Clin Obstet Gynecol. 1992;35:871-883.
64. Clore NJ. Dehydroepiandrosterone and body fat. Obes Res. 1995;Nov 3(suppl 4):613S-616S.
65. Taniguchi S, Yanase T, Haji M, Ishibashi K, Takayanagi R, Nwata H. The antiobesity effects of dehydroepiandros-terone in castrated or non castrated obese Zucker male rats. Obes Res. 1995;Dec 3(suppl 5):693S-643S.
66. Danenberg HD, Ben-Yehuda A, Zakay-Rones Z, Friedman G. Dehydroepiandrosterone enhances influenza immunization in aged mice. Ann NY Acad Sci. 1995;774:297-299.
67. Khaw KT. Dehydroepiandrosterone, dehydroepiandrosterone sulfate and cardiovascular disease. J Endocrinol. 1996;150(suppl):S149-S153.
68. Casson PR, Buster JE. DHEA replacement after menopause: HRT 2000 or nostrum of the '90s? Contemp Obstet Gynecol. 1997;42:119-133.
69. van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus: results of a double-blind placebo-controlled, randomized clinical trial. Arthritis Rheum. 1995;38:1826-1831.
70. National Institute on Aging, National Institutes of Health, http://www.nih.gov:80/nia/new/press/antihorm.htm.
71. Tyler V. The Honest Herbal: A Sensible Guide to the Use of Herbs and Related Remedies. Binghamton, NY: Parmaceutical Products Press/The Haworth Press; 1993.
72. Centers for Disease Control and Prevention. Water hemlock poisoning - Maine, 1992. JAMA. 1994;271:1475.
73. Dreikorn K, Schonhofer PS. Status of phytotherapeutic drugs in treatment of benign prostatic hyperplasia. Urologe A. 1995;34:119-129.
74. Clark LC, Combs GF, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA. 1996;276:1957-1963.
75. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet. 1996;347:781-786.
76. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease: The Alzheimer's Disease Cooperative. N Engl J Med. 1997;336:1216-1222.
77. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure: DASH Collaborative Research Group. N Engl J Med. 1997;336:1117-1124.
78. Rimm EB, Ascherio A, Giovannucci E, Spiegelman D, Stampfer MJ, Willett WC. Vegetable, fruit, and cereal fiber intake and risk of coronary heart disease among men. JAMA. 1996;275:447-451.
79. Gillman MW, Cupples LA, Gagnon D, et al. Protective effect of fruits and vegetables on development of stroke in men.JAMA. 1995;273:1113-1117.
80. Tucker KL, Mahnken B, Wilson PW, Jacques P, Selhub J. Folic acid fortification of the food supply: potential benefits and risks for the elderly population. JAMA. 1996;276:1879-1885.
81. Dossey L. Alternative Therapies in Health and Medicine. Aliso Viejo, CA: Innovision Communications/American Association of Critical Care Nurses; 1995
82. Micozzi MS. The Journal of Alternative and Complementary Medicine: Research on Paradigm, Practice and Policy. New York, NY: Mary Ann Liebert; 1995.
83. Tufts Diet and Nutrition Newsletter. P.O. Box 57857, Boulder, CO 80322-7857.
84. Health. P.O. Box 56876, Boulder, CO 80323-6876.
85. Prevention Magazine. Rodale Press. 33 East Minor Street, Emmaus, PA 18098.
86. Herbs for Health. Interweave Press. 201 East Fourth Street, Loveland, CO 80537-5655.
87. American Botanical Council. PO Box 201660, Austin, TX 78720.
88. Nutrition Research Newsletter. 32 North Dean Street, Englewood, NJ 07631.